
Abatacept 1-6mg/kg / Abatacept TNF

13.2.2 Anakinra

Anakinra IL-1 IL-1 cryopirin CAPS 1-2mg/kg 5mg/kg 100mg JIA 2 cryopirin CAPS

13.2.3 Canakinumab

Canakinumab 1 (IL1) cryopirin (CAPS) 1-4mg/kg cryopirin (CAPS)

13.2.4

6 IL6 JIA 15-30kg 8mg/kg 30kg 12mg/kg 4-10mg/kg JIA ()

13.3

rituximab (anti-CD20) tofacitinib (JAK-3 inhibitor) and other immunosuppressants. The use of these drugs is associated with an increased risk of infection and malignancy. Patients should be monitored for signs and symptoms of infection and malignancy. The use of rituximab is associated with an increased risk of serious infections, including pneumonia, tuberculosis, and hepatitis. The use of tofacitinib is associated with an increased risk of serious infections, including pneumonia, tuberculosis, and hepatitis. The use of other immunosuppressants is associated with an increased risk of serious infections, including pneumonia, tuberculosis, and hepatitis.